Brinzolamide

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

布林佐胺是一种高度特异性、非竞争性、可逆碳酸酐酶抑制剂。

Brinzolamide is a highly specific, non-competitive, reversible carbonic anhydrase inhibitor. Carbonic anhydrase (CA) is an enzyme found in many tissues of the body including the eye. It catalyzes the reversible reaction involving the hydration of carbon dioxide and the dehydration of carbonic acid. In humans, carbonic anhydrase exists as a number of isoenzymes, the most active being carbonic anhydrase II (CA-II). Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport. The result is a reduction in intraocular pressure. Brinzolamide is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. (In Vivo):Brinzolamide (7.5 mg or 12 mg) implanted in a silicone matrix is extremely well tolerated and provides sustained release of brinzolamide and significant reduction in intraocular pressure (IOP) for up to 28 days with no adverse effects or signs of toxicity in normotensive NZW rabbits.

——

Brinzolamide (7.5 mg or 12 mg) implanted in a silicone matrix is extremely well tolerated and provides sustained release of brinzolamide and significant reduction in intraocular pressure (IOP) for up to 28 days with no adverse effects or signs of toxicity in normotensive NZW rabbits.The pharmacokinetic parameters of Brinzolamide in rabbits.Animal Model:Rabbits Dosage:7.5 mg, 12 mg Administration:Brinzolamide silicone matrix implant placed in the episcleral space Result:Resulted in a significant IOP reduction of 4.6 mmHg on days 10-28, with concentrations of 12 mg.

AL 4862 | Azopt

Membrane Transporter/Ion Channel

Carbonic Anhydrase

Carbonic anhydrase II

Other Indications

——

138890-62-7

383.51

C12H21N3O5S3

>98% (HPLC)

DMSO: 77 mg/mL (200.77 mM)

CCN[C@H]1CN(S(=O)(=O)C2=C1C=C(S2)S(=O)(=O)N)CCCOC

——

(-20℃)

With Ice Pack

≥ 2 years